{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:10:29Z","timestamp":1789049429223,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease is characterized by excessive hepatic fat accumulation. Some individuals frequently present elevated gamma-glutamyl transferase (GGT) levels without fatty liver ultrasound images and other abnormal liver enzymes levels. However, whether these individuals are at an elevated risk for developing fatty liver is unclear. We compared fatty liver change rates and risk factors between individuals with frequently elevated GGT levels and those with normal levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We designed a retrospective cohort study on the basis of complete medical checkup records. One group of individuals had presented normal serum GGT levels during the observation period (Normal-GGT group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092713). Another group had had abnormal elevated serum GGT levels frequently (Abnormal-GGT group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009264). We determined the fatty liver change incident rates before and after propensity score matching. We explored confounding factors affecting fatty changes in each group using univariate and multivariate Cox models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The change incidence rates were 5.80\/1000 and 10.02\/1000 person-years in the Normal-GGT and Abnormal-GGT groups, respectively. After propensity score matching, the incidence rates were 3.08\/1000 and 10.18\/1000 person-years in the Normal-GGT and Abnormal-GGT groups, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026). The factors associated with fatty liver changes in the Normal-GGT group included body mass index (BMI), hemoglobin, alanine aminotransferase (ALT), albumin, triglyceride (TG), fasting blood sugar, and high-density lipoprotein levels. Those in the Abnormal-GGT group were platelet counts and TG. In our multivariable analysis, BMI, ALT, albumin, and TG levels were independent predictors of fatty changes in the Normal-GGT group, and high TG level was the only independent predictor in the Abnormal-GGT group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The incidence rate of fatty liver change in the Abnormal-GGT group was higher than that in the Normal-GGT group. Consecutive elevated GGT levels increase the risk for fatty liver, and high TG levels in those individuals further independently increase the risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-020-01369-x","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T05:03:44Z","timestamp":1594357424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Hideki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhisa","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Fukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kadono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Asaeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Nakatsugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Tomatsuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Nakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatomo","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"1369_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221\u201331.","journal-title":"N Engl J Med"},{"key":"1369_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology."},{"key":"1369_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/dme.13565","volume":"35","author":"AL Sberna","year":"2018","unstructured":"Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, et al. European Association for the Study of the liver (EASL), European Association for the Study of diabetes (EASD) and European Association for the Study of obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with type 2 diabetes. Diabet Med. 2018;35:368\u201375.","journal-title":"Diabet Med"},{"key":"1369_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00535-015-1050-7","volume":"50","author":"S Watanabe","year":"2015","unstructured":"Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364\u201377.","journal-title":"J Gastroenterol"},{"key":"1369_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0016-5085(19)34921-2","volume":"45","author":"AM Ruttenburg","year":"1963","unstructured":"Ruttenburg AM, Goldbarg JA, Pineda EP. Serum gamma-glutamyl transpeptidase activity in hepatobiliary pancreatic disease. Gastroenterology. 1963;45:43\u20138.","journal-title":"Gastroenterology."},{"key":"1369_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/clinchem\/31.6.797","volume":"31","author":"E Nemes\u00e1nszky","year":"1985","unstructured":"Nemes\u00e1nszky E, Lott JA. Gamma-glutamyltransferase and its isoenzymes: progress and problems. Clin Chem. 1985;31:797\u2013803.","journal-title":"Clin Chem"},{"key":"1369_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1742-1241.2012.02959.x","volume":"66","author":"CF Liu","year":"2012","unstructured":"Liu CF, Zhou WN, Fang NY. Gamma-glutamyltransferase levels and risk of metabolic syndrome: a meta-analysis of prospective cohort studies. Int J Clin Pract. 2012;66:692\u20138.","journal-title":"Int J Clin Pract"},{"key":"1369_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ijcp.12507","volume":"69","author":"SK Kunutsor","year":"2015","unstructured":"Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose\u2013response meta-analysis. Int J Clin Pract. 2015;69:136\u201344.","journal-title":"Int J Clin Pract"},{"key":"1369_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10715760410001694026","volume":"38","author":"DH Lee","year":"2004","unstructured":"Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38:535\u20139.","journal-title":"Free Radic Res"},{"key":"1369_CR10","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.freeradbiomed.2004.06.032","volume":"37","author":"JS Lim","year":"2004","unstructured":"Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR, Lee DH. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Radic Biol Med. 2004;37:1018\u201323.","journal-title":"Free Radic Biol Med"},{"key":"1369_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ihj.2017.11.017","volume":"70","author":"S Arasteh","year":"2018","unstructured":"Arasteh S, Moohebati M, Avan A, Esmaeili H, Ghazizadeh H, Mahdizadeh A, et al. Serum level of gamma-glutamyl transferase as a biomarker for predicting stenosis severity in patients with coronary artery disease. Indian Heart J. 2018;70:788\u201392.","journal-title":"Indian Heart J"},{"key":"1369_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11255-016-1429-2","volume":"49","author":"ZW Shen","year":"2017","unstructured":"Shen ZW, Xing J, Wang QL, Faheem A, Ji X, Li J, et al. Association between serum \u03b3-glutamyltransferase and chronic kidney disease in urban Han Chinese: a prospective cohort study. Int Urol Nephrol. 2017;49:303\u201312.","journal-title":"Int Urol Nephrol"},{"key":"1369_CR13","first-page":"95","volume":"8","author":"E Ikai","year":"1994","unstructured":"Ikai E, Honda R, Yamada Y. Serum gamma-glutamyl transpeptidase level and blood pressure in nondrinkers: a possible pathogenetic role of fatty liver in obesity-related hypertension. J Hum Hypertens. 1994;8:95\u2013100.","journal-title":"J Hum Hypertens"},{"key":"1369_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865\u201373.","journal-title":"Hepatology."},{"key":"1369_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0009-9260(05)80350-2","volume":"43","author":"AE Joseph","year":"1991","unstructured":"Joseph AE, Saverymuttu SH. al-Sam S, cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43:26\u201331.","journal-title":"Clin Radiol"},{"key":"1369_CR16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/hep.23135","volume":"50","author":"R Haring","year":"2009","unstructured":"Haring R, Wallaschofski H, Nauck M, D\u00f6rr M, Baumeister SE, V\u00f6lzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009;50:1403\u201311.","journal-title":"Hepatology."},{"key":"1369_CR17","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263\u201376.","journal-title":"World J Gastroenterol"},{"key":"1369_CR18","first-page":"1388","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","journal-title":"J Hepatol"},{"key":"1369_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/20014091084227","volume":"38","author":"JB Whitfield","year":"2001","unstructured":"Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38:263\u2013355.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1369_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/0004563215597010","volume":"53","author":"S Bulusu","year":"2016","unstructured":"Bulusu S, Sharma M. What does serum \u03b3-glutamyltransferase tell us as a cardiometabolic risk marker? Ann Clin Biochem. 2016;53:312\u201332.","journal-title":"Ann Clin Biochem"},{"key":"1369_CR21","doi-asserted-by":"publisher","first-page":"10J","DOI":"10.1016\/S0002-9149(03)00611-8","volume":"92","author":"WA Hsueh","year":"2003","unstructured":"Hsueh WA, Qui\u00f1ones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92:10J\u20137J.","journal-title":"Am J Cardiol"},{"key":"1369_CR22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1053\/j.gastro.2010.06.009","volume":"139","author":"R Loomba","year":"2010","unstructured":"Loomba R, Rao F, Zhang L, Khandrika S, Ziegler MG, Brenner DA, et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta 2-adrenergic receptor genetic variation in twins. Gastroenterology. 2010;139:836\u201345 45.e1.","journal-title":"Gastroenterology"},{"key":"1369_CR23","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/liv.13221","volume":"36","author":"SK Kunutsor","year":"2016","unstructured":"Kunutsor SK. Gamma-glutamyltransferase-friend or foe within? Liver Int. 2016;36:1723\u201334.","journal-title":"Liver Int"},{"key":"1369_CR24","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/hep.23593","volume":"51","author":"EK Speliotes","year":"2010","unstructured":"Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham heart study. Hepatology. 2010;51:1979\u201387.","journal-title":"Hepatology."},{"key":"1369_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3892\/br.2014.309","volume":"2","author":"M Tomizawa","year":"2014","unstructured":"Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, et al. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep. 2014;2:633\u20136.","journal-title":"Biomed Rep"},{"key":"1369_CR26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/liv.12977","volume":"36","author":"Y Fukuda","year":"2016","unstructured":"Fukuda Y, Hashimoto Y, Hamaguchi M, Fukuda T, Nakamura N, Ohbora A, et al. Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int. 2016;36:713\u201320.","journal-title":"Liver Int"},{"key":"1369_CR27","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1111\/liv.12318","volume":"34","author":"S Zelber-Sagi","year":"2014","unstructured":"Zelber-Sagi S, Salomone F, Yeshua H, Lotan R, Webb M, Halpern Z, et al. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int. 2014;34:e128\u201335.","journal-title":"Liver Int"},{"key":"1369_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/gast.2001.23256","volume":"120","author":"AJ Sanyal","year":"2001","unstructured":"Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183\u201392.","journal-title":"Gastroenterology"},{"key":"1369_CR29","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343\u201351.","journal-title":"J Clin Invest"},{"key":"1369_CR30","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387\u201395.","journal-title":"Hepatology."},{"key":"1369_CR31","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","volume":"47","author":"A Lonardo","year":"2015","unstructured":"Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, Argo CK, Ballestri S, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47:997\u20131006.","journal-title":"Dig Liver Dis"},{"key":"1369_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/obr.12407","volume":"17","author":"L Li","year":"2016","unstructured":"Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17:510\u20139.","journal-title":"Obes Rev"},{"key":"1369_CR33","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862\u201373.","journal-title":"J Hepatol"},{"key":"1369_CR34","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/j.1440-1746.2012.07222.x","volume":"27","author":"CJ Liu","year":"2012","unstructured":"Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27:1555\u201360.","journal-title":"J Gastroenterol Hepatol"},{"key":"1369_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/alcalc\/agw002","volume":"51","author":"Y Osaki","year":"2016","unstructured":"Osaki Y, Kinjo A, Higuchi S, Matsumoto H, Yuzuriha T, Horie Y, et al. Prevalence and trends in alcohol dependence and alcohol use disorders in Japanese adults; results from periodical nationwide surveys. Alcohol Alcohol. 2016;51:465\u201373.","journal-title":"Alcohol Alcohol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01369-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-020-01369-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01369-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T19:38:17Z","timestamp":1625859497000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01369-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1369"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01369-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-19610\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-19610\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethical committee of Japanese Red Cross Society Kyoto Daiichi Hospital approved the study. We conducted the study in accordance with the tenets of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}